Novaquest Capital Management

Novaquest Capital Management invests in late-stage biopharmaceutical products through a model it calls product finance. It also forms partnerships with animal health companies. Its financing deals have supported drug developers without issuing new shares in some cases.

What Novaquest Capital Management offers

• Product finance — funding tied to specific biopharma products late in development.
• Royalty monetisation — for example, a financing with FibroGen.
• Non-dilutive finance — for example, a deal with Hansa Biopharma supporting its antibody-cleaving enzyme platform.
• Equity rounds — it took part in a Series C round for TARGAN, a poultry vaccine delivery company.
• Animal health partnerships — collaboration with companies in that field.

Key facts

• Focus: biopharmaceutical products
• Stage: late-stage